Medexus Pharmaceuticals Inc.
Medexus Pharmaceuticals Inc.
- Market cap
- $187.61M
Your view on MDP.TO
Overview
What the company does, where it operates, and who runs it.
About Medexus Pharmaceuticals Inc.
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Kenneth d'Entremont
- Headquarters
- 35 Nixon Road, Bolton, ON, CA
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Kenneth d'Entremont
- Headquarters
- 35 Nixon Road, Bolton, ON, CA
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy.
The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication.
Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms.
The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.
Stock Data
Price chart, volume, and trading data.
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Medexus Pharmaceuticals Inc. from FRC's valuation model, read against the market price. MDP.TO last traded at C$5.97; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Medexus Pharmaceuticals Inc.. Starting points for Medexus Pharmaceuticals Inc.: EPS -C$0.04, beta 1.68 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Medexus Pharmaceuticals Inc.. Trailing twelve-month EPS for Medexus Pharmaceuticals Inc. stands at -C$0.04. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Hold
Analyst ratings
1 rating- Strong Buy0
- Buy0
- Hold1
- Sell0
- Strong Sell0
Earnings per share estimates
| Per share | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Mar 2027 | Next yearYear to Mar 2028 |
|---|---|---|---|---|
| Average estimate | $0.07 | $0.08 | $0.20 | $0.59 |
| Lowest estimate | $0.03 | $0.05 | $0.16 | $0.43 |
| Highest estimate | $0.10 | $0.11 | $0.26 | $0.81 |
| Number of analysts | 3 | 3 | 4 | 4 |
| A year ago | $0.001 | −$0.111 | −$0.071 | — |
| Growth vs a year ago | — | — | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Mar 2027 | Next yearYear to Mar 2028 |
|---|---|---|---|---|
| Average estimate | $30.90M | $31.17M | $120.56M | $144.21M |
| Lowest estimate | $26.07M | $28.67M | $118.51M | $136.74M |
| Highest estimate | $33.50M | $32.21M | $121.57M | $148.67M |
| Number of analysts | 5 | 5 | 5 | 6 |
| A year ago | $25.32M | $24.65M | $99.33M | — |
| Growth vs a year ago | +22.0% | +26.4% | +21.4% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Medexus Pharmaceuticals Inc.. Medexus Pharmaceuticals Inc. has reported as a listed company since 2014. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| BNXT.CNBioNxt Solutions Inc. | Healthcare | Drug Manufacturers - Specialty & Generic | $76.7M | ||
| CRDL.TOCardiol Therapeutics Inc. | Healthcare | Drug Manufacturers - Specialty & Generic | $164.1M | ||
| CXXI.CNC21 Investments Inc. | Healthcare | Drug Manufacturers - Specialty & Generic | $58.4M | ||
| DB.VDecibel Cannabis Company Inc. | Healthcare | Drug Manufacturers - Specialty & Generic | $54.4M | ||
| IAN.CNiAnthus Capital Holdings, Inc. | Healthcare | Drug Manufacturers - Specialty & Generic | $34.1M | ||
| INNO.CNInnoCan Pharma Corporation | Healthcare | Medical - Pharmaceuticals | $36.1M | ||
| MRMD.CNMariMed Inc. | Healthcare | Drug Manufacturers - Specialty & Generic | $51.4M | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| SBMFFSino Biopharmaceutical Limited | Healthcare | OTC | $15.0B | ||
| SCNXScienture Holdings, Inc. | Healthcare | NASDAQ | $4.1M | ||
| SCYXSCYNEXIS, Inc. | Healthcare | NASDAQ | $17.7M | ||
| SDEVStablecoin Development Corp. | Healthcare | AMEX | $29.7M | ||
| SDGCFSundrug Co.,Ltd. | Healthcare | OTC | $3.3B | ||
| SGIPFSugi Holdings Co.,Ltd. | Healthcare | OTC | $2.9B | ||
| SHMNSOHM, Inc. | Healthcare | OTC | $1.9M | ||
| SKVISkinvisible, Inc. | Healthcare | OTC | $1.1M | ||
| SNNCSibannac, Inc. | Healthcare | OTC | $197,600 | ||
| SPPHSpencer Pharmaceutical Inc. | Healthcare | OTC | $29,436 | ||
| SYDRFDelota Corp. | Healthcare | OTC | $2.9M | ||
| SYMQYSymBio Pharmaceuticals Limited | Healthcare | OTC | $27.2M | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| DFICDimensional - International Core Equity 2 ETF | $15.4B in assets | 0.00% | |
| DFAXDimensional - World ex US Core Equity 2 ETF | $11.7B in assets | 0.00% | |
| EGIF.TOExemplar Growth and Income Fund | $3M in assets | 0.93% | |
Largest holders first, then the funds most concentrated in MDP.TO.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Medexus Pharmaceuticals Inc.. Coverage tracks Medexus Pharmaceuticals Inc. within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Medexus Pharmaceuticals Inc.